# Biosimilar Contract Manufacturing Market

> Biosimilar Contract Manufacturing Market Research Report Information By Product (Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins), By Production Technology (Mammalian and Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 18.9%
- **2024:** $ 7.73 Billion
- **2025:** $ 9.19 Billion
- **2035:** $ 51.9 Billion
- **Key Players:** Companies such as Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Roche (CH), Amgen (US), Sandoz (CH) are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/10382-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** June 23, 2026

**URL:** https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903

---

## Market Summary

The Global Biosimilar Contract Manufacturing Market size was valued at USD 7.729 Billion in 2024, and the market is projected to grow from USD 9.189 Billion in 2025 to USD 51.9 Billion by 2035, registering a CAGR of 18.9% during the forecast period 2025–2035. North America led the market in 2024 with over 45% share, generating around USD 3.48 Billion in revenue.
 
Rising demand for cost-efficient biologics and increasing patent expirations of blockbuster drugs are key growth drivers, encouraging pharmaceutical companies to outsource biosimilar production to specialized contract manufacturers, enhancing scalability, reducing costs, and accelerating time-to-market for advanced therapeutic solutions globally.
 
According to WHO, biologics account for nearly 50% of global pharmaceutical spending, while biosimilars can reduce treatment costs by 20–30%, significantly improving access; additionally, over $80 billion worth of biologics are expected to lose patent protection globally, driving biosimilar manufacturing demand.

## Market Drivers

### Cost-Effectiveness of Biosimilars

The cost-effectiveness of biosimilars compared to their reference biologics is a significant driver for the Biosimilar Contract Manufacturing Industry. As healthcare costs continue to rise, payers and patients are increasingly seeking more affordable treatment options. Biosimilars offer a viable solution, often priced 20-30% lower than their reference products.
 
This price differential not only makes biosimilars more accessible to patients but also encourages healthcare providers to prescribe them. Consequently, pharmaceutical companies are motivated to engage in contract manufacturing to produce biosimilars, thereby expanding their portfolios and meeting market demand. The global market is thus likely to thrive as the emphasis on cost-effective healthcare solutions intensifies.
 

- According to World Bank health expenditure data, global healthcare spending continues to rise across developed and emerging economies, increasing pressure on healthcare systems to adopt cost-efficient treatment solutions. Biosimilars, often offering significant savings compared with reference biologics, are becoming increasingly attractive for payers, providers, and patients seeking affordable therapeutic alternatives.

### Regulatory Support and Frameworks

The establishment of supportive regulatory frameworks for biosimilars is a crucial factor influencing the Biosimilar Contract Manufacturing Industry. Regulatory agencies are increasingly recognizing the importance of biosimilars in enhancing patient access to essential medications. For instance, streamlined approval processes and guidelines for biosimilar development have been implemented in various regions, facilitating faster market entry.
 
This regulatory support not only encourages pharmaceutical companies to explore biosimilar options but also enhances the confidence of contract manufacturers in investing in biosimilar production capabilities. As a result, the global market is likely to experience accelerated growth, driven by the favorable regulatory landscape that promotes the development and commercialization of biosimilars.
 

- PubMed-published studies have demonstrated increasing regulatory acceptance of biosimilars globally, with expanding evidence supporting comparable safety and efficacy profiles. Streamlined approval pathways and growing regulatory confidence are encouraging greater biosimilar development activity while supporting contract manufacturers investing in large-scale production capabilities.

### Growing Focus on Personalized Medicine

The increasing emphasis on personalized medicine is shaping the Biosimilar Contract Manufacturing Industry. As healthcare shifts towards tailored treatment approaches, the demand for biosimilars that can be customized to meet individual patient needs is rising. This trend is prompting pharmaceutical companies to explore biosimilar options that align with personalized treatment paradigms.
 
Additionally, the integration of advanced analytics and data-driven insights into biosimilar development is enhancing the ability to create targeted therapies. Consequently, contract manufacturers are likely to adapt their production capabilities to accommodate the growing demand for personalized biosimilars, thereby contributing to the expansion of the market.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders is a primary driver for the Biosimilar Contract Manufacturing Industry. As these conditions require long-term treatment, the demand for biologics, including biosimilars, is expected to surge. According to recent estimates, the prevalence of chronic diseases is projected to increase significantly, leading to a heightened need for affordable treatment options.
 
This trend is likely to encourage pharmaceutical companies to invest in biosimilar development and contract manufacturing, as they seek to provide cost-effective alternatives to expensive biologic therapies. Consequently, the market is poised for growth as manufacturers align their capabilities to meet the increasing demand for biosimilars that address chronic health issues.

### Technological Advancements in Manufacturing Processes

Technological advancements in biomanufacturing processes are transforming the Biosimilar Contract Manufacturing Industry. Innovations such as single-use technologies, continuous manufacturing, and improved cell culture techniques are enhancing production efficiency and reducing costs. These advancements enable contract manufacturers to produce biosimilars at a larger scale while maintaining quality and compliance with regulatory standards.
 
As technology continues to evolve, it is expected that the capabilities of contract manufacturers will expand, allowing for the development of a wider range of biosimilars. This trend is likely to attract more pharmaceutical companies to partner with contract manufacturers, further propelling the growth of the market.

## Future Outlook

The Biosimilar Contract Manufacturing Market size is projected to reach USD 51.9 Billion by 2035, growing at a CAGR of 18.9%, driven by increasing demand for cost-effective biologics and regulatory support.

**New opportunities:**

- Expansion into emerging markets with tailored biosimilar solutions.
- 
- Investment in advanced bioprocessing technologies for efficiency.
- Strategic partnerships with biotech firms for co-development initiatives.

By 2035, the market is expected to solidify its position as a leader in biopharmaceutical manufacturing.

## Segment Insights

### By Product: Recombinant Glycosylated Proteins (Largest) vs. Recombinant Non-glycosylated Proteins (Fastest-Growing)

The market is significantly driven by recombinant glycosylated proteins, which hold the largest Biosimilar Contract Manufacturing Market share at 62% due to their wide applications in therapeutic areas, including [oncology](https://www.marketresearchfuture.com/reports/oncology-drugs-market-12355) and autoimmune diseases. Their complex structure allows for better functionality, making them preferable for a variety of treatments. In contrast, recombinant non-glycosylated proteins are witnessing rapid adoption, particularly in the fields of hormone therapy and enzyme replacements, showcasing their growing relevance in the market.

Fujifilm Diosynth Biotechnologies continues expanding large-scale biologics manufacturing infrastructure to support growing demand for complex recombinant glycosylated proteins. The company's advanced biomanufacturing facilities are designed to accommodate commercial-scale production of high-value biosimilars used extensively across oncology and autoimmune disease treatment applications.

### By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing)

The mammalian production technology segment dominates, holding the largest Biosimilar Contract Manufacturing Market share at 68% due to its wide acceptance and proven efficacy in biopharmaceutical production. This method is preferred for producing complex proteins, offering superior post-translational modifications that are crucial for therapeutic efficacy. On the other hand, non-mammalian systems are rapidly gaining traction as they present cost-effective alternatives, particularly for simpler biosimilars. This diversification points to a market evolution where companies are expanding their technology capabilities. Growth trends indicate that as the demand for biosimilars rises globally, the need for efficient and scalable production methods becomes paramount. The mammalian segment is likely to continue its dominance, while advancements in non-mammalian technologies, such as yeast and bacterial systems, are expected to accelerate growth. Factors driving this shift include increasing regulatory approvals for non-mammalian products and advancements in genetic engineering that enhance yield and productivity. As companies strive for innovation and cost reduction, both segments will play critical roles in shaping the future of biosimilar manufacturing.

Catalent's biologics manufacturing network utilizes advanced mammalian cell-culture technologies to support production of complex therapeutic proteins. Mammalian expression systems remain the preferred platform for many biosimilars due to superior post-translational modification capabilities that are essential for maintaining therapeutic efficacy and product consistency.

### By Application: Oncology (Largest) vs. Blood Disorders (Fastest-Growing)

The Biosimilar Contract Manufacturing Market is witnessing a diverse distribution across its application segments, with a significant share of 55%. Oncology stands out as the largest segment, accounting for a significant portion of the overall market. This dominance is largely attributed to the rising prevalence of cancer and the increasing demand for effective treatment options. In contrast, the Blood Disorders segment, while smaller in market share, is rapidly gaining traction in the industry, driven by advancements in manufacturing processes and a growing patient population requiring these therapies. Growth trends within this market segment indicate a robust increase in both segments. Oncology is propelled by heightened investment in oncology research and development, as well as successful outcomes of biosimilars in clinical settings. Meanwhile, the Blood Disorders market is characterized by continuous innovations and a surge in regulatory approvals, positioning it as the fastest-growing area within the sector as more patients are diagnosed and treated for various blood-related conditions.

WuXi Biologics continues supporting oncology-focused biosimilar development through integrated biologics manufacturing services. According to global cancer statistics, millions of new cancer cases are diagnosed annually, driving sustained demand for affordable oncology biologics and reinforcing oncology's dominant position within biosimilar contract manufacturing activities.

## Regional Market Share Analysis

### North America : Leading Innovation and Demand

North America leads in the Biosimilar Contract Manufacturing Market size, accounting for over 45% of the global revenue in 2024. The region benefits from advanced healthcare infrastructure, increasing adoption of biosimilars, and supportive regulatory frameworks. The demand is driven by rising healthcare costs and the need for affordable biologics, with the FDA actively promoting biosimilar approvals to enhance competition and patient access.

- CDC data indicates that approximately 6 in 10 U.S. adults live with at least one chronic disease, while 4 in 10 adults have two or more chronic conditions. The growing burden of chronic illness continues supporting demand for affordable biologic therapies and biosimilars across North America.

The United States is the primary player in this market, with significant contributions from companies like Amgen and Catalent. Canada also plays a role, albeit smaller, in the biosimilars landscape. The competitive environment is characterized by the presence of major players such as Samsung Biologics and Lonza Group, which are expanding their manufacturing capabilities to meet the growing demand for biosimilars in the region.

- Amgen remains a leading biosimilar developer with multiple FDA-approved biosimilar products across oncology and inflammatory disease categories. The company's expanding biosimilar portfolio demonstrates increasing market acceptance of biosimilars and highlights North America's strong commercial and regulatory environment for biosimilar manufacturing growth.

### Europe : Regulatory Support and Growth

Europe market size was valued at USD 2.32 billion in 2024, making it the second-largest regional market with a 30% share. The region's growth is fueled by a robust regulatory framework that encourages the development and approval of biosimilars, alongside increasing healthcare costs and a rising demand for affordable treatment options. The European Medicines Agency (EMA) has been instrumental in streamlining the approval process, which has led to a surge in biosimilar products entering the market.

- The European Medicines Agency has approved more than 100 biosimilar medicines since establishing the world's first biosimilar regulatory pathway. This robust regulatory framework has significantly accelerated biosimilar adoption across Europe, supporting market expansion and enhancing patient access to cost-effective biologic therapies.

Leading countries in this region include Germany, the UK, and France, which are home to several key players like Boehringer Ingelheim and Sandoz. The competitive landscape is marked by a mix of established pharmaceutical companies and emerging biotech firms, all vying for a share of the growing biosimilars market. The presence of strong manufacturing capabilities and innovation in bioprocessing technologies further enhances Europe's position in the global biosimilar landscape.

### Asia-Pacific : Emerging Market Potential

Asia-Pacific is rapidly emerging as a significant player in the market, holding approximately 15% of the global market share. The region's growth is driven by increasing healthcare expenditures, a large patient population, and a growing acceptance of biosimilars. Countries like China and India are leading this trend, supported by favorable government policies aimed at boosting local manufacturing and reducing healthcare costs.

China is the largest market in the region, with companies like Wuxi Biologics and Fujifilm Diosynth Biotechnologies leading the charge. India is also making strides with its robust pharmaceutical sector, focusing on biosimilars to cater to both domestic and international markets. The competitive landscape is evolving, with both local and international players investing in advanced manufacturing technologies to enhance production efficiency and quality.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually developing its market, currently holding about 5% of the global market share. The growth is primarily driven by increasing healthcare needs, rising awareness of biosimilars, and government initiatives aimed at improving healthcare access. Countries like South Africa and the UAE are at the forefront, with efforts to establish local manufacturing capabilities and attract foreign investment in the biosimilars sector.

The competitive landscape is still in its infancy, with a few local players and international companies exploring opportunities in the region. The presence of key players is limited, but there is significant potential for growth as governments focus on enhancing healthcare infrastructure and regulatory frameworks. As the market matures, it is expected to attract more investment and innovation in biosimilar manufacturing.

## Competitive Benchmarking

The Biosimilar Contract Manufacturing Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the growing acceptance of biosimilars across various therapeutic areas. Key players such as Samsung Biologics (South Korea), Lonza Group (Switzerland), and Boehringer Ingelheim (Germany) are strategically positioning themselves through innovation and operational excellence.
Samsung Biologics (South Korea) has focused on expanding its manufacturing capabilities, while Lonza Group (Switzerland) emphasizes partnerships to enhance its service offerings. Boehringer Ingelheim (Germany) is leveraging its extensive experience in biologics to strengthen its market presence, collectively shaping a competitive environment that prioritizes quality and efficiency.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains.
 
The global market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive advancements in technology and operational practices that set industry standards.
 
In August Samsung Biologics (South Korea) announced the opening of a new state-of-the-art facility aimed at increasing its production capacity for biosimilars. This strategic move is likely to enhance its competitive edge by meeting the rising global demand for biosimilars, thereby positioning the company as a leader in the contract manufacturing space. The facility is expected to incorporate advanced technologies that streamline production processes, further solidifying Samsung's reputation for quality and reliability.
 
In September Lonza Group (Switzerland) entered into a strategic partnership with a leading biopharmaceutical company to co-develop a new biosimilar product. This collaboration underscores Lonza's commitment to innovation and its ability to leverage external expertise to accelerate product development. Such partnerships are indicative of a broader trend in the industry, where collaboration is becoming essential for navigating the complexities of biosimilar development and manufacturing.
 
In July Boehringer Ingelheim (Germany) launched a new initiative focused on sustainability in its manufacturing processes. This initiative aims to reduce the environmental impact of biosimilar production, aligning with global sustainability goals. By prioritizing eco-friendly practices, Boehringer Ingelheim not only enhances its corporate responsibility but also appeals to a growing segment of environmentally conscious consumers and stakeholders.
 
As of October the competitive trends in the market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in manufacturing processes. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and sustainable practices, reflecting the industry's shift towards a more holistic approach to value creation.

## Recent News & Developments

**September 2022 **Ropidoxuridine, the company's principal clinical sensitizer drug candidate, will be manufactured by Shuttle Pharmaceuticals Holdings Inc. in accordance with a contract with TCG GreenChem, Inc. This drug will be used in the formulation of a drug product that will be tested in clinical studies of Ropidoxuridine and RT of malignancies.

## Report Scope

| MARKET SIZE 2024 | 7.729(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 9.189(USD Billion) |
| MARKET SIZE 2035 | 51.9(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Roche (CH), Amgen (US), Sandoz (CH) |
| Segments Covered | Product, Production Technology, Application, Region |
| Key Market Opportunities | Growing demand for cost-effective biologics drives expansion in the market. |
| Key Market Dynamics | Rising demand for cost-effective biologics drives competition among biosimilar contract manufacturers amid evolving regulatory landscapes. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Biosimilar Contract Manufacturing Market?**
A: As of 2024, the market valuation was 7.729 USD Billion.

**Q: What is the projected market size for the Biosimilar Contract Manufacturing Market by 2035?**
A: The market is projected to reach 51.9 USD Billion by 2035.

**Q: What is the expected CAGR for the market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 18.9%.

**Q: Which companies are considered key players in the Biosimilar Contract Manufacturing Market?**
A: Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, and Fujifilm Diosynth Biotechnologies.

**Q: What are the main product segments in the market?**
A: The main product segments include Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins, each valued at approximately 3.8645 USD Billion.

**Q: How does the production technology segment break down in terms of valuation?**
A: The production technology segment is valued at 4.5 USD Billion for Mammalian and 3.229 USD Billion for Non-Mammalian technologies.

**Q: What applications are driving growth in the Biosimilar Contract Manufacturing Market?**
A: Key applications include Oncology, Blood Disorders, and Chronic & Autoimmune Disorders, with Oncology valued at 1.5 USD Billion.

**Q: What is the valuation of the Chronic & Autoimmune Disorders application segment?**
A: The Chronic & Autoimmune Disorders application segment is valued at 1.8 USD Billion.

**Q: How does the market for Rheumatoid Arthritis biosimilars compare to other applications?**
A: The Rheumatoid Arthritis application segment is valued at 1.5 USD Billion, indicating a robust market presence.

**Q: What trends are influencing the growth of the Biosimilar Contract Manufacturing Market?**
A: The market appears to be influenced by increasing demand for cost-effective biologics and advancements in production technologies.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903*